Cryofocus Medtech (Shanghai) Co., Ltd. (HKG:6922)
Hong Kong · Delayed Price · Currency is HKD 4.990
+0.140 (2.89%)
At close: Jul 17, 2025, 4:00 PM HKT
HKG:6922 Revenue
In the year 2024, Cryofocus Medtech (Shanghai) had annual revenue of 53.53M CNY with 30.72% growth. Cryofocus Medtech (Shanghai) had revenue of 34.06M in the half year ending December 31, 2024, with 102.20% growth.
Revenue
53.53M CNY
Revenue Growth
+30.72%
P/S Ratio
20.95
Revenue / Employee
193.95K CNY
Employees
276
Market Cap
1.19B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 53.53M | 12.58M | 30.72% |
| Dec 31, 2023 | 40.95M | 13.80M | 50.83% |
| Dec 31, 2022 | 27.15M | 4.72M | 21.06% |
| Dec 31, 2021 | 22.43M | 13.37M | 147.69% |
| Dec 31, 2020 | 9.05M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| Sino Biopharmaceutical | 30.72B |
| WuXi Biologics | 19.87B |
| Akeso | 2.26B |
| CSPC Pharmaceutical Group | 28.99B |